Ono will assist with Vertex's clinical trials for povetacicept and handle marketing approvals in Japan and South Korea, focusing on IgAN and pMN with possible additional uses.

Distributed vertex-centric graph systems, or VC-systems, have achieved tremendous success in the industry. A common usage pattern of VC-systems is multi-processing, or the concurrent processing of ...

We propose a scalable graph processing hardware accelerator called NOVA that is based on a novel vertex management architecture that decouples the execution of reduction and propagation operations in ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

The graphite found in your favorite pencil could have instead been the diamond your mother always wears. What made the ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...

Vertex Pharmaceuticals is currently pushing against the $467.85 resistance level as its stock maintains an upward trend.

Yahoo Finance is chronicling the latest news and updates on Trump's tariffs.

PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.